BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground - 2We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- 3‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- 4What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- 5Excited visitors for NASA's moon launch jockey for prime views
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- Warship sunk by British fleet, remains of sailor found after 225 years
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- New science points to 4 distinct types of autism
